Edition:
India

Obseva SA (OBSV.OQ)

OBSV.OQ on NASDAQ Stock Exchange Global Select Market

10.33USD
1:30am IST
Change (% chg)

$0.65 (+6.71%)
Prev Close
$9.68
Open
$9.68
Day's High
$10.45
Day's Low
$9.68
Volume
7,532
Avg. Vol
14,522
52-wk High
$19.40
52-wk Low
$9.27

Latest Key Developments (Source: Significant Developments)

Obseva To Increase Issued Share Capital
Thursday, 18 Jul 2019 

July 18 (Reuters) - OBSEVA SA ::OBSEVA TO INCREASE ISSUED SHARE CAPITAL BY CREATING ADDITIONAL TREASURY SHARES.NEW SHARES, TO BE ISSUED OUT OF COMPANY'S AUTHORIZED CAPITAL, WILL BE FULLY SUBSCRIBED FOR BY OBSEVA USA INC.NEW SHARES TO BE LISTED ON SIX SWISS EXCHANGE ON OR AROUND JULY 23, 2019.TRANSACTION HAS BEEN DECIDED TO PROVIDE GROUP WITH ADDITIONAL TREASURY SHARES THAT CAN BE USED IN FUTURE TO RAISE FUNDS IN AN EFFICIENT MANNER.BOARD OF DIRECTORS APPROVED AN INCREASE OF ITS SHARE CAPITAL FROM 45,491,616 TO 48,555,664.TO ISSUE 3,064,048 NEW REGISTERED SHARES AT AN ISSUE PRICE OF 1/13 OF A SWISS FRANC EACH.  Full Article

Obseva Appoints Dr. Elizabeth Garner As Chief Medical Officer
Monday, 1 Jul 2019 

July 1 (Reuters) - OBSEVA SA ::OBSEVA APPOINTS INDUSTRY EXPERT AS CHIEF MEDICAL OFFICER TO FURTHER ADVANCE ITS PHASE 3 CLINICAL PROGRAMS.APPOINTMENT OF DR. ELIZABETH GARNER AS CHIEF MEDICAL OFFICER AND MEMBER OF EXECUTIVE COMMITTEE, EFFECTIVE 15 JULY 2019.  Full Article

Obseva SA Presents Clinical Data From Phase III Implant 2 Trial Of Nolasiban In IVF At ASRM
Wednesday, 10 Oct 2018 

Oct 9 (Reuters) - :PRESENTS CLINICAL DATA FROM PHASE III IMPLANT 2 TRIAL OF NOLASIBAN IN IVF AT AMERICAN SOCIETY OF REPRODUCTIVE MEDICINE (ASRM) ANNUAL MEETING.NOLASIBAN TREATMENT SHOWN TO SIGNIFICANTLY INCREASE LIVE BIRTH RATE IN RANDOMIZED CLINICAL TRIAL OF PATIENTS UNDERGOING IN VITRO FERTILIZATION.SECONDARY ENDPOINT OF MISCARRIAGE RATE FROM WEEKS 2 TO 24 OF GESTATION SHOWED A FAVOURABLE IMPACT FROM NOLASIBAN TREATMENT.OBSEVA-TOLERABILITY AND SAFETY PROFILE OF NOLASIBAN COMPARABLE TO PLACEBO, NO INCREASE IN SERIOUS ADVERSE EVENTS, IN ECTOPIC PREGNANCY, NOR IN CONGENITAL BIRTH DEFECTS.  Full Article

Obseva SA Reports Additional Positive Phase 3 Results Of Implant 2 Trial
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - Obseva SA ::REPORTS ADDITIONAL POSITIVE PHASE 3 RESULTS OF IMPLANT 2 TRIAL SHOWING SIGNIFICANT INCREASE OF LIVE BIRTH RATE (LBR) FOLLOWING IVF WITH SINGLE EMBRYO TRANSFER (SET).PHASE 3 IMPLANT 2 TRIAL RESULTS SHOWED LIVE BIRTH RATE INCREASED BY UP TO 35% WITH NOLASIBAN TREATMENT.LIVE BIRTH RATE IS A KEY SECONDARY ENDPOINT IN IMPLANT 2 TRIAL OF NOLASIBAN IN IVF, RESULTS SHOW SIGNIFICANT BENEFIT IN FAVOR OF NOLASIBAN.  Full Article

Obseva Q2 Loss Per Share $0.49
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Obseva SA ::OBSEVA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.49.Q2 EARNINGS PER SHARE VIEW $-0.53 -- THOMSON REUTERS I/B/E/S.PHASE 2B EDELWEISS CLINICAL TRIAL OF LINZAGOLIX (OBE2109) IN ENDOMETRIOSIS RELATED PELVIC PAIN ACHIEVED PRIMARY AND SECONDARY ENDPOINTS.  Full Article

Obseva SA Achieves Primary And Secondary Endpoints For Edelweiss Phase 2B Clinical Trial Of Linzagolix
Monday, 18 Jun 2018 

June 18 (Reuters) - Obseva SA ::OBSEVA SA ACHIEVES PRIMARY AND SECONDARY ENDPOINTS FOR EDELWEISS PHASE 2B CLINICAL TRIAL OF LINZAGOLIX (OBE2109) IN WOMEN WITH ENDOMETRIOSIS.OBSEVA SA - LINZAGOLIX WAS OBSERVED TO BE SAFE AND WELL TOLERATED IN PHASE 2B CLINICAL TRIAL.  Full Article

Obseva SA To Seek Six Share Listing
Friday, 1 Jun 2018 

June 1 (Reuters) - Obseva SA ::OBSEVA SA TO SEEK SIX SHARE LISTING.OBSEVA SA - INTENTION TO REQUEST LISTING OF SHARES ON SIX SWISS EXCHANGE UNDER SIX'S INTERNATIONAL REPORTING STANDARD.OBSEVA SA - TRADING OF OBSEVA'S SHARES ON NASDAQ WILL CONTINUE IN ADDITION TO SIX LISTING.  Full Article

Obseva Reports Q1 Loss Per Share $0.54
Wednesday, 16 May 2018 

May 16 (Reuters) - Obseva SA ::OBSEVA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.54.Q1 EARNINGS PER SHARE VIEW $-0.47 -- THOMSON REUTERS I/B/E/S.SAYS AS OF MARCH 31, 2018, OBSEVA HAD CASH AND CASH EQUIVALENTS OF $95.4 MILLION..  Full Article

Obseva Q4 Loss Per Share $0.48
Friday, 9 Mar 2018 

March 9 (Reuters) - Obseva Sa ::OBSEVA REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.48.Q4 EARNINGS PER SHARE VIEW $-0.56 -- THOMSON REUTERS I/B/E/S.  Full Article

Obseva Initiates Phase 2A Clinical Trial Of Obe022 In Preterm Labor
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Obseva Sa ::OBSEVA INITIATES PROLONG, THE PHASE 2A CLINICAL TRIAL OF OBE022 IN PRETERM LABOR.OBSEVA SA - ‍OBSEVA EXPECTS TO ANNOUNCE PRELIMINARY RESULTS FROM 60 PATIENTS IN PART B OF PROLONG TRIAL IN LATE 2018​.  Full Article